Volition 14 10 191859 2

Nu.Q®

Detecting cancer early to save lives.

A simple, cost effective blood test for cancer.

Cancer is a devastating disease that touches many peoples’ lives, accounting for approximately 10 million deaths worldwide each year.¹

Early diagnosis is the best way to improve someone’s chances of surviving cancer; however, current population-wide screening tests (such as mammograms and colonoscopies) are often invasive and unpleasant. They can also be expensive, causing many people to miss routine screening. There are no population screening tests at all for some types of cancer, including aggressive forms of the disease such as ovarian or pancreatic cancers. Unfortunately, many patients are therefore diagnosed too late, when their cancer has already spread, and treatment is more difficult.

1. gco/iarc.fr - as of 23 Nov 2021

We believe that Nu.Q® can become a cost effective routine blood test for multiple types of cancer, allowing doctors to check off an extra box along with other routine blood tests like cholesterol during an annual wellness visit.

Nu.Q® tests have further potential applications in clinical oncology beyond cancer detection. Being able to use epigenetic information from tumor cells’ nucleosomes could also help physicians select the best treatment for each patient, monitor their response and the disease progression.

“With an aging population cancer is becoming even more common. Our tests will give doctors new tools to screen for cancer, monitor response to treatment and potentially for remission.”

Dr Jason Terrell, Chief Medical Officer

We are currently investigating the potential use of Nu.Q® tests in a range of cancers and clinical settings:

  • Population Screening

    Lung Cancer

    Colorectal cancer

    Our tests can identify patterns of epigenetic marks on circulating nucleosomes that are specific to colorectal cancer cells.

  • Risk Stratification and Diagnostic Aid

    Non-Hodgkin Lymphoma

    To improve the speed of diagnostic tests, as the current testing protocol is lengthy and often delays the start of treatment.

    Lung Cancer

    To improve the specificity of low-dose CT scans for high-risk individuals and help avoid unnecessary biopsies.

    Colorectal Cancer

    To improve the specificity of the fecal immunochemical test (FIT) and help avoid unnecessary colonoscopies.

    Prostate Cancer

    To improve discrimination between high-grade prostate cancers requiring treatment and low-grade “watch and wait” tumors.

  • Disease and Treatment Monitoring

    Non-Hodgkin Lymphoma

    Monitoring patient response to treatment for Non-Hodgkin Lymphoma.

    Colorectal Cancer

    Monitoring patients’ minimal residual disease and remission.